Financhill
Back

Insmed Quote, Financials, Valuation and Earnings

Insmed Price Quote

$70.51
+0.07 (+1.58%)
(Updated: December 21, 2024 at 5:32 AM ET)

Insmed Key Stats

Sell
50
Insmed (INSM) is a Sell

Day range:
$68.80 - $71.07
52-week range:
$21.92 - $80.53
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
31.92
P/B ratio:
26.07%

Volume:
5.7M
Avg. volume:
1.9M
1-year change:
154.2%
Market cap:
$12.6B
Revenue:
$305.2M
EPS:
$-5.55

How Much Does Insmed Make?

Data Unavailable

Is Insmed Growing As A Company?

Data Unavailable

Insmed Stock Price Performance

  • Did Insmed Stock Go Up Last Month?
    Insmed share price went down by -3.07% last month
  • Did INSM's Share Price Rise Over The Last Year?
    INSM share price rose by 154.2% over the past 1 year

What Is Insmed 52-Week High & Low?

  • What Is Insmed’s 52-Week High Share Price?
    Insmed has traded as high as $80.53 over the past 52 weeks
  • What Is Insmed’s 52-Week Low Share Price?
    Insmed has traded as low as $21.92 over the past 52 weeks

Insmed Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Insmed?

Data Unavailable

Is Insmed Cash Flow Positive?

Data Unavailable

Insmed Return On Invested Capital

Data Unavailable

Insmed Earnings Date & Stock Price

  • What Is Insmed's Stock Price Today?
    A single share of INSM can be purchased today for 70.44
  • What Is Insmed’s Stock Symbol?
    Insmed trades on the nasdaq under the ticker symbol: INSM
  • When Is Insmed’s Next Earnings Date?
    The next quarterly earnings date for Insmed is scheduled on February 21, 2025
  • When Is INSM's next ex-dividend date?
    Insmed's next ex-dividend date is December 22, 2024
  • How To Buy Insmed Stock?
    You can buy Insmed shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.

Insmed Competitors

  • Who Are Insmed's Competitors?
    Below is a list of companies who compete with Insmed or are related in some way:
    • Alnylam Pharmaceuticals Inc (ALNY)
    • Collegium Pharmaceutical Inc (COLL)
    • Cytokinetics Inc (CYTK)
    • Amicus Therapeutics Inc (FOLD)
    • Krystal Biotech Inc (KRYS)

Insmed Dividend Yield

Data Unavailable

Insmed Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -1.91%
Revenue: 18.15% 0.21%

Analyst Recommendations

Buy Recommendations: 0
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 0.00
Downside from Last Price: -100%

Major Shareholders

Data Unavailable